Startups
Edit
http://www.imugene.com/
Imugene | Cancer Immunotherapies
TrustedLast activity: 28.11.2025
Active
Imugene (ASX; IMU) is an oncology focused biopharmaceutical company developing clinical immunotherapeutics to advance cancer care. The Company’s lead product is HER-Vaxx, a proprietary immunotherapeutic vaccine that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com
Overview
Location
Australia, New South Wales, Sydney
Employees
11-50
Phone
+61 3 9824 5254
Total raised
$4.65M
Founded date
2013
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 14, 2025 | Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL | Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1b trial of azer-cel, an allogeneic off-t... |
| Jul 20, 2023 | RenovoRx and Imugene Announce plans to Deliver Oncolytic Virus Therapy Using Trans-Arterial Micro-Perfusion Platform. | Collaboration will explore trans-arterial delivery of Imugene’s CF33 oncolytic virus utilizing RenovoRx’s TAMP therapy platform. (NASDAQ:RNXT) Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline f... |
| Dec 20, 2021 | Imugene : Appendix 2A and IMUOB Option Underwriting Agreement | Option Underwriting Agreement and Appendix 2A Remaining IMUOB Options Exercised, ASX Announcement only_______________________________________________________________________________________ use20 December 2021 Imugene Limited (ASX: IMU), a ... |
Reviews 0
FAQ about Imugene | Cancer Immunotherapies
When was Imugene | Cancer Immunotherapies founded?
Imugene | Cancer Immunotherapies was founded in 2013.
How much funding has Imugene | Cancer Immunotherapies raised?
Imugene | Cancer Immunotherapies has raised $4.65M in total across 1 funding round.
What has the press written about Imugene | Cancer Immunotherapies?
Parsers VC has collected 4 articles mentioning Imugene | Cancer Immunotherapies, among them “Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL” (Jul 14, 2025) and “RenovoRx and Imugene Announce plans to Deliver Oncolytic Virus Therapy Using Trans-Arterial Micro-Perfusion Platform.” (Jul 20, 2023).
Is Imugene | Cancer Immunotherapies still active?
Yes, Imugene | Cancer Immunotherapies is active; its latest activity on Parsers VC dates from Nov 28, 2025.